Active Not RecruitingNCT04733534
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
PHASE2 · 120 planned enrolment
- Countries listed
- 1
- Registry update
- September 30, 2026
Source-linked trial list
The registrations behind this number.
Verify the exact trial registrations behind a company, intervention, programme or topic count.
Exact trial list
6 matching trial registrations
- Intervention Fisetin
Showing 1–6 of 6. Every record below meets all the filters shown above.
RecruitingNCT06399809
Fisetin to Reduce Senescence and Mobility Impairment in PAD
PHASE2 · 34 planned enrolment
- Countries listed
- 1
- Registry update
- April 15, 2026
TerminatedNCT04537299
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes
PHASE2 · 20 planned enrolment
- Countries listed
- 1
- Registry update
- August 26, 2025
CompletedNCT04313634
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
PHASE2 · 74 planned enrolment
- Countries listed
- 1
- Registry update
- July 22, 2024
UnknownNCT04815902
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
PHASE1 · PHASE2 · 100 planned enrolment
- Countries listed
- 1
- Registry update
- April 16, 2024
UnknownNCT05025956
Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
PHASE1 · PHASE2 · 68 planned enrolment
- Countries listed
- 1
- Registry update
- April 16, 2024